If GLP-1s work too well, what happens next for metabolic disease?

The success of GLP-1–based therapies has fundamentally reshaped how we think about obesity. What was once considered a chronic, difficult-to-treat condition is now increasingly manageable and, in some cases, dramatically reversible.

That raises an important and somewhat uncomfortable question for the industry: what happens if these drugs work too well?

Obesity is not the whole story

There is a growing narrative that if we can effectively reduce excess weight, we can “solve” metabolic disease. While weight loss is undeniably important, it is not the entire picture.

Metabolic disease is more complex than obesity alone. There are patients who are not overweight, yet still develop type 2 diabetes and other metabolic complications. These cases highlight an important reality: weight is a contributor, but not the sole driver of metabolic dysfunction.

If obesity is significantly reduced across populations, we may indeed see a contraction in certain segments of the market. But metabolic disease will not disappear. It will evolve and likely become more concentrated in patients with underlying metabolic dysregulation that extends beyond weight alone.

A smaller market, but a more complex one

If highly effective therapies reduce obesity prevalence, the overall market for metabolic drugs could shift.

This is not necessarily a negative outcome; it would represent meaningful progress in public health. But it also means the industry must prepare for a future in which patient populations may become smaller, treatment needs may become more nuanced, and differentiation becomes more critical.

The next phase of innovation will focus on targeting specific metabolic pathways with greater precision.

The maintenance question

At the same time, another key question is emerging: what happens after weight loss?

Today, many GLP-1 therapies are positioned as long-term, even lifelong treatments. Patients are often told that, once they begin therapy, they will need to remain on it indefinitely to maintain results.

But does that model truly make sense?

If a patient reaches a healthy weight and improves their metabolic profile, the idea of remaining on therapy indefinitely raises both clinical and economic questions. It also introduces a broader conversation around patient expectations, adherence, and long-term outcomes.

The future of metabolic care will likely require a more balanced approach, one that considers when to initiate treatment, how to optimise outcomes, and – critically – how to sustain those outcomes over time.

Beyond weight loss: What really matters

Another shift underway is a growing recognition that how weight is lost matters just as much as how much is lost.

We are seeing increasing attention on factors such as fat distribution, particularly visceral fat, as well as waist circumference and its link to metabolic risk and overall body composition.

These markers may prove more meaningful than weight loss alone in determining long-term health outcomes.

The next phase of the GLP-1 era

The first wave of GLP-1 therapies has demonstrated what is possible. The second wave will define what is sustainable.

Success in the next phase will depend on improving tolerability and adherence while expanding focus beyond obesity to address the full spectrum of metabolic diseases. This includes developing therapies that not only treat conditions effectively, but also support long-term maintenance and help patients transition toward healthier, more sustainable lifestyles.

This last point is critical. Pharmacological intervention can drive significant change, but it cannot operate in isolation. Long-term success will require a combination of medical treatment, behavioural support, and patient engagement.

A shift in perspective

The industry often frames the future of obesity treatment as a question of scale: how many patients can be treated, and how large the market can become.

But the more important question may be different: what happens when we start to solve the problem?

If GLP-1s and next-generation therapies continue to improve, we may find ourselves in a very different landscape, one where the goal is not just to treat disease, but to manage, maintain, and potentially prevent it over time.

That future will require new thinking, not only in drug development, but in how we define success in metabolic health.

About the author

Prior to his appointment as MetaVia’s chief executive officer and president, Hyung Heon Kim was the General Counsel and a senior vice president of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production, and sale of pharmaceuticals, medical devices, and APIs. Kim has been serving as a member of MetaVia’s Board since July 2021. He previously served as executive director of Dong-A ST from 2018 through 2020 and as head of international legal affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. Since April 2021, Kim has served as a director of AnaPath Services GmbH, a private, Swiss-based provider of scientific research and development services. He previously served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. Kim received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.